Genewiz, a genomics services provider under Azenta Life Sciences, has launched Gene Synthesis 2.0, an updated platform aimed at enhancing the efficiency of gene design and ordering for researchers. This new platform features three distinct packages—Sprint, Flex, and Flex—designed to provide a streamlined and intuitive ordering experience. Trey Martin, president of Genewiz, emphasizes that researchers can now design cloning strategies, select vectors, evaluate sequence complexity, and place orders in just minutes, significantly accelerating the research process.
The upgraded platform also incorporates advanced codon optimization capabilities, merging traditional heuristic techniques with machine-learning models that are trained on a high-expression dataset. This innovative approach is expected to enhance expression reliability across various organisms and sequence architectures while allowing customers to maintain control over their design choices. Martin notes that Gene Synthesis 2.0 is tailored to the current demands of researchers, where speed, clarity, and reliability are critical at every stage of their work.
As Gene Synthesis 2.0 is showcased at ASGCT this week at booth 915, it represents a significant advancement in the tools available for rapidly evolving fields such as antibody discovery, AI-enabled biology, and gene and cell therapy, enabling scientists to expedite their research efforts effectively.
Open the full market picture for your next decision →
